他汀类药物可减少动脉粥样硬化形成中的血管炎症：潜在分子机制的综述。

Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms.

机构信息

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; Center for Molecular Cardiology, University of Zurich, Wagistrasse 12, 8952 Schlieren, Switzerland.

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy; IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, 10 Largo Benzi, 16132, Genoa, Italy.

出版信息

Int J Biochem Cell Biol. 2020 May;122:105735. doi: 10.1016/j.biocel.2020.105735. Epub 2020 Feb 29.

DOI:10.1016/j.biocel.2020.105735

PMID:32126319

Abstract

Chronic inflammation enhances the detrimental role of dyslipidaemia during atherogenesis. Statins are among the most effective anti-atherosclerotic medications, being able to impact on both cardiovascular morbidity and mortality. Although these molecules have been first described as lipid-lowering medications, several lines of evidence suggest additional benefits through their "pleiotropic" anti-atherosclerotic activities. Specifically, statins can modulate vascular atherosclerotic inflammation by directly improving functions of endothelial cells, vascular smooth muscle cells, platelets, and immune cells. Here, we discuss basic and clinical evidence to provide an update on the molecular mechanisms underlying the protective anti-inflammatory role of statins in atherogenesis.

摘要

慢性炎症增强了血脂异常在动脉粥样硬化形成过程中的有害作用。他汀类药物是最有效的抗动脉粥样硬化药物之一，能够影响心血管发病率和死亡率。尽管这些分子最初被描述为降脂药物，但有几条证据表明它们通过“多效性”抗动脉粥样硬化活性具有额外的益处。具体来说，他汀类药物可以通过直接改善内皮细胞、血管平滑肌细胞、血小板和免疫细胞的功能来调节血管动脉粥样硬化炎症。在这里，我们讨论了基础和临床证据，提供了他汀类药物在动脉粥样硬化形成中抗炎保护作用的分子机制的最新信息。